|
1
|
Chang ET and Adami HO: The enigmatic
epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol
Biomarkers Prev. 15:1765–1777. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guigay J: Advances in nasopharyngeal
carcinoma. Curr Opin Oncol. 20:264–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hawking F: Suramin: with special reference
to onchocerciasis. Adv Pharmacol Chemother. 15:289–322. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song S, Yu B, Wei Y, Wientjes MG and Au
JL: Low-dose suramin enhanced paclitaxel activity in
chemotherapy-naive and paclitaxel-pretreated human breast xenograft
tumors. Clin Cancer Res. 10:6058–6065. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhargava S, Hotz B, Hines OJ, Reber HA,
Buhr HJ and Hotz HG: Suramin inhibits not only tumor growth and
metastasis but also angiogenesis in experimental pancreatic cancer.
J Gastrointest Surg. 11:171–178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vogelzang NJ, Karrison T, Stadler WM,
Garcia J, Cohn H, Kugler J, et al: A phase II trial of suramin
monthly × 3 for hormone-refractory prostate carcinoma. Cancer.
100:65–71. 2004.
|
|
7
|
Agrawal D, Chen T, Irby R, et al:
Osteopontin identified as lead marker of colon cancer progression
using pooled sample expression profiling. J Natl Cancer Inst.
94:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rudland PS, Platt-Higgins A, El-Tanani M,
et al: Prognostic significance of the metastasis-associated protein
osteopontin in human breast cancer. Cancer Res. 62:3417–3427.
2002.PubMed/NCBI
|
|
9
|
Coppola D, Szabo M, Boulware D, Muraca P,
Alsarraj M, Chambers AF and Yeatman TJ: Correlation of osteopontin
protein expression and pathological stage across a wide variety of
tumor histologies. Clin Cancer Res. 10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shang S, Plymoth A, Ge S, Feng Z, Rosen
HR, Sangrajrang S, Hainaut P, Marrero JA and Beretta L:
Identification of osteopontin as a novel marker for early
hepatocellular carcinoma. Hepatology. 55:483–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gong M, Lu Z, Fang G, Bi J and Xue X: A
small interfering RNA targeting osteopontin as gastric cancer
therapeutics. Cancer Lett. 272:148–159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geissinger E, Weisser C, Fischer P,
Schartl M and Wellbrock C: Autocrine stimulation by osteopontin
contributes to antiapoptotic signalling of melanocytes in dermal
collagen. Cancer Res. 62:4820–4828. 2002.PubMed/NCBI
|
|
13
|
Yang G, Zhang Y, Wu J, Xiong J, Deng H,
Wang J, Yang C and Zhu Z: Osteopontin regulates growth and
migration of human nasopharyngeal cancer cells. Mol Med Rep.
4:1169–1173. 2011.PubMed/NCBI
|
|
14
|
Wong TS, Kwong DL, Sham J, Wei WI, Kwong
YL and Yuen AP: Elevation of plasma osteopontin level in patients
with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol.
31:555–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hui EP, Sung FL, Yu BK, et al: Plasma
osteopontin, hypoxia, and response to radiotherapy in
nasopharyngeal cancer. Clin Cancer Res. 14:7080–7087. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McCain DF, Wu L, Nickel P, Kassack MU,
Kreimeyer A, Gagliardi A, Collins DC and Zhang ZY: Suramin
derivatives as Inhibitors and activators of protein-tyrosine
phosphatases. J Biol Chem. 279:14713–14725. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chevillard S, Pouillart P, Beldjord C,
Asselain B, Beuzeboc P, Magdelenat H and Vielh P: Sequential
assessment of multidrug resistance phenotype and measurement of
S-phase fraction as predictive markers of breast cancer response to
neoadjuvant chemotherapy. Cancer. 77:292–300. 1996. View Article : Google Scholar
|
|
18
|
Kolfschoten GM, Hulscher TM, Pinedo HM and
Boven E: Drug resistance features and S-phase fraction as possible
determinants for drug response in a panel of human ovarian cancer
xenografts. Br J Cancer. 83:921–927. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang G, He B and Weber GF: Growth factor
signaling induces metastasis genes in transformed cells: molecular
connection between Akt kinase and osteopontin in breast cancer. Mol
Cell Biol. 23:6507–6519. 2003. View Article : Google Scholar
|
|
20
|
Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH,
Yoo H, Shin SH, Song ES and Lee SH: Hyaluronic acid induces
osteopontin via the phosphatidylinositol 3-kinase/Akt pathway to
enhance the motility of human glioma cells. Cancer Res. 65:686–691.
2005.PubMed/NCBI
|
